Expert Opinion on Investigational Drugs

Papers
(The H4-Index of Expert Opinion on Investigational Drugs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond92
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer85
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?80
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases78
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials75
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects69
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?64
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential63
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors58
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer50
Fezolinetant in the treatment of vasomotor symptoms associated with menopause48
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies45
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs42
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas41
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis41
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress39
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma36
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer34
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease33
Monoclonal antibody therapies in the management of SARS-CoV-2 infection32
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma32
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine31
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics30
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers29
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action29
Therapies in preclinical and clinical development for Angelman syndrome28
Investigational drugs for the treatment of diffuse large B-cell lymphoma27
Immunotherapies in clinical development for biliary tract cancer27
0.070704936981201